Xencor (XNCR) Tops Q2 EPS by $1.43

Xencor (NASDAQ: XNCR) reported Q2 EPS of $0.87, $1.43 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $67.4 million versus the consensus estimate of $19.61 million.

“Xencor is applying its leading protein engineering tools and XmAb technology to overcome historical challenges in creating therapeutic molecules from bispecific antibodies or cytokines. For our most advanced clinical programs, we recently initiated a Phase 2 clinical study for XmAb717, our PD-1 x CTLA-4 bispecific antibody, in metastatic prostate cancer, and we plan to initiate a Phase 2 study of plamotamab in lymphoma. Our cytokine portfolio is rapidly advancing with XmAb306, our long-acting IL-15 for oncology, and XmAb564, our IL-2 for autoimmune disease, both of which are in Phase 1 studies,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “We are also at the forefront of efforts to engage CD28 to selectively activate T cells, and we plan to initiate clinical studies in 2022 for XmAb808, our B7-H3 x CD28 bispecific antibody, as well as our third clinical cytokine program, an IL-12-Fc candidate.”

“Additionally, Vir Biotechnology and GSK’s sotrovimab was recently authorized for the treatment of mild-to-moderate COVID-19, becoming the third antibody incorporating XmAb technology to be made commercially available for patients. The licensing of our XmAb technologies expands their application to areas of medicine outside our internal focus and provides us with important sources of non-dilutive capital, which we use to advance and expand our broad internal portfolio of novel bispecific antibodies and cytokine drug candidates.”

GUIDANCE:

Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations into 2024. Xencor expects to end 2021 with between $475 million and $500 million in cash, cash equivalents and marketable securities.

For earnings history and earnings-related data on Xencor (XNCR) click here.

You May Also Be Interested In

• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
• Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss